S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)

Evolus - EOLS Stock Forecast, Price & News

$8.85
+0.05 (+0.57%)
(As of 10/5/2022 04:31 PM ET)
Add
Compare
Today's Range
$8.73
$8.98
50-Day Range
$7.76
$13.11
52-Week Range
$5.06
$14.34
Volume
329,096 shs
Average Volume
506,381 shs
Market Capitalization
$496.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.33

Evolus MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
73.3% Upside
$15.33 Price Target
Short Interest
Healthy
5.34% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.27
Upright™ Environmental Score
News Sentiment
1.55mentions of Evolus in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$1.25 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.12) to ($0.28) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.51 out of 5 stars

Medical Sector

186th out of 1,072 stocks

Pharmaceutical Preparations Industry

77th out of 534 stocks

EOLS stock logo

About Evolus (NASDAQ:EOLS) Stock

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Receive EOLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evolus and its competitors with MarketBeat's FREE daily newsletter.

EOLS Stock News Headlines

This Options Play Could Turn That Frown Upside Down - RealMoney
Recap: Evolus Q2 Earnings - Benzinga
See More Headlines
Receive EOLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evolus and its competitors with MarketBeat's FREE daily newsletter.

EOLS Company Calendar

Last Earnings
8/02/2022
Today
10/05/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EOLS
Fax
N/A
Employees
167
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.33
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+73.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$-46,810,000.00
Pretax Margin
-59.31%

Debt

Sales & Book Value

Annual Sales
$99.67 million
Book Value
$1.47 per share

Miscellaneous

Free Float
52,000,000
Market Cap
$496.44 million
Optionable
Optionable
Beta
2.02

Key Executives

  • Mr. David MoatazediMr. David Moatazedi (Age 44)
    Pres, CEO & Director
    Comp: $1.23M
  • Dr. Rui Avelar C.CFP (Age 60)
    Dip.SportMed, M.D., Chief Medical Officer and Head of R&D
    Comp: $660.08k
  • Mr. David K. Erickson
    VP of Investor Relations
  • Mr. Jeffrey J. Plumer
    Gen. Counsel
  • Mr. Kurt Knab
    VP of Sales
  • Ms. Crystal Muilenburg (Age 42)
    Chief Marketing Officer
  • Ms. Jessica Novak
    Sr. VP of HR













EOLS Stock - Frequently Asked Questions

Should I buy or sell Evolus stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" EOLS shares.
View EOLS analyst ratings
or view top-rated stocks.

What is Evolus' stock price forecast for 2022?

6 Wall Street research analysts have issued 12-month target prices for Evolus' shares. Their EOLS share price forecasts range from $10.00 to $20.00. On average, they expect the company's share price to reach $15.33 in the next twelve months. This suggests a possible upside of 75.0% from the stock's current price.
View analysts price targets for EOLS
or view top-rated stocks among Wall Street analysts.

How have EOLS shares performed in 2022?

Evolus' stock was trading at $6.51 at the beginning of the year. Since then, EOLS stock has increased by 34.6% and is now trading at $8.76.
View the best growth stocks for 2022 here
.

When is Evolus' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our EOLS earnings forecast
.

How were Evolus' earnings last quarter?

Evolus, Inc. (NASDAQ:EOLS) posted its earnings results on Tuesday, August, 2nd. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.28) by $0.14. The business earned $37.16 million during the quarter, compared to analyst estimates of $36.83 million. Evolus had a negative net margin of 59.35% and a negative trailing twelve-month return on equity of 107.14%.

What guidance has Evolus issued on next quarter's earnings?

Evolus issued an update on its FY 2022 earnings guidance on Tuesday, August, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $150.00 million-$150.00 million, compared to the consensus revenue estimate of $150.26 million.

What is David Moatazedi's approval rating as Evolus' CEO?

1 employees have rated Evolus Chief Executive Officer David Moatazedi on Glassdoor.com. David Moatazedi has an approval rating of 100% among the company's employees. This puts David Moatazedi in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Evolus own?
When did Evolus IPO?

(EOLS) raised $65 million in an initial public offering on Thursday, February 8th 2018. The company issued 5,000,000 shares at $12.00-$14.00 per share. Cantor and Mizuho Securities served as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers.

What is Evolus' stock symbol?

Evolus trades on the NASDAQ under the ticker symbol "EOLS."

How do I buy shares of Evolus?

Shares of EOLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Evolus' stock price today?

One share of EOLS stock can currently be purchased for approximately $8.76.

How much money does Evolus make?

Evolus (NASDAQ:EOLS) has a market capitalization of $491.44 million and generates $99.67 million in revenue each year. The company earns $-46,810,000.00 in net income (profit) each year or ($1.41) on an earnings per share basis.

How many employees does Evolus have?

The company employs 167 workers across the globe.

How can I contact Evolus?

Evolus' mailing address is 520 Newport Center Dr. Suite 1200, Newport Beach CA, 92660. The official website for the company is www.evolus.com. The company can be reached via phone at (949) 284-4555 or via email at ir@evolus.com.

This page (NASDAQ:EOLS) was last updated on 10/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.